Spesolimab injection

Spesolimab, formerly known as Spesolimab, is a humanized antagonistic monoclonal IgG1 antibody that binds to IL-36R and blocks IL-36R activation induced by human IL-36α, IL-36β, and IL-36γ, thereby inhibiting pro-inflammatory and pro-fibrotic pathways in inflammatory skin diseases. According to an earlier press release by Boehringer Ingelheim, Spesolimab is an investigational therapy that specifically targets the IL-36 pathway to treat acute attacks of GPP. In addition, the drug is also being developed for the prevention of acute attacks of GPP and the treatment of other neutrophilic skin diseases, such as palmoplantar pustulosis and suppurative hidradenitis. Generalized Pustular Psoriasis (GPP) is a rare, heterogeneous, life-threatening neutrophilic skin disease. The clinical course of patients varies, with some patients experiencing relapses of the disease with repeated acute attacks, while others have persistent diseases with intermittent acute attacks. Although acute episodes of GPP vary in severity, if left untreated, complications such as sepsis and multisystem organ failure may be life-threatening.